microconstants > aboutus > Our History

Our History

2017-02-21 14:08:22
Timeline
2007:  MicroConstants China was established in 2007 by the founder and president of MicroConstants, Inc., a GLP-compliant bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, USA. Located in Beijing, MicroConstants China is dedicated to providing premier quality preclinical and clinical bioanalytical and pharmacokinetics services to pharmaceutical and biotech companies worldwide. 
 
2008: Microconstants laboratory was audited and proved to be in accordance with FDA GLP standard. 
 
2009: Microconstants firstly provided technical services for an international customer.
 
2010: Microconstants achieved the accreditation of its bioanalytical laboratory by the China National Accreditation Service for Conformity Assessment (CNAS), a Chinese government agency that monitors quality systems of analytical laboratories based on ISO-17025 guidelines.
 
2011: MicroConstants China Inc., conducted preclinical PK studies and provided full-service early stage clinical trial management in China, has received a renewed Endorsement of Compliance with the OECD Principles of GLP at their newly established facility in Beijing. The Endorsement was initially awarded in May 2011 following an inspection at MicroConstants China previous location. Being the first bioanalytical laboratory received OECD GLP compliance in China and accredited by CNAS, MicroConstants China can conduct various analytical service with its HPLC and LC/MS system and the test results can be used for regulatory submission with CFDA, FDA, EMA and other regulatory agencies worldwide.
 
2012: Microconstants provided technical services for the top 10 international pharmaceutical companies.
 
2013: Microconstants established the strategic cooperation with the largest centralized cardiac safety laboratory (ERT) worldwidely.
 
2014: MicroConstants China established a fully owned subsidiary, Microtech China Inc., to serve as an incubator for new drug development.  It has gained the Greater China rights for a Phase II stage polypeptide drug candidate for the treatment of cancer.  It has established a global drug development network to expedite the drug development process with significant cost savings.
 
2015: Microconstants set up some network in Tianjing, Shenyang and Shanghai.
 
2016: Microconstants set up a branch office in Guangzhou.